Categories
World News

Floods in Europe and China disrupt international delivery, provide chains

The floods in China and Europe are another “body blow” for global supply chains, the CEO of a shipping company told CNBC on Monday.

“Seldom goes a week without something new,” says Tim Huxley, CEO of Mandarin Shipping.

Shipping has already experienced massive disruptions this year. As parts of the world recovered from the pandemic, increased spending resulted in a shortage of containers, causing delays and driving up prices.

In April one of the largest container ships in the world got wedged in the Suez Canal and stopped traffic for almost a week. The waterway is one of the busiest in the world, carrying about 12% of all trade.

In June, a spike in COVID cases in southern China caused further delays in the region’s ports, pushing shipping prices soaring again.

“Broken railway connections” due to floods in Europe

Heavy rains and floods have devastated parts of Western Europe. Some of the worst floods occurred in Germany and Belgium. Parts of Switzerland, Luxembourg and the Netherlands are also affected.

“This will really disrupt the supply chain because the rail links have all been cut,” Huxley told CNBC’s Squawk Box Asia.

These include railways from the Czech Republic and Slovakia to the German ports of Rotterdam and Hamburg, which are “seriously disrupted”.

“And that will delay freight movements back and forth,” he said. “This is going to really mess up the industry.”

Huxley pointed to Thyssenkrupp and stated that the German steel giant could not get any raw materials because of the flooding.

“That will ultimately affect industries like automotive, home appliances and the like,” he said.

S&P Global Platts reported, citing a customer letter, that Thyssenkrupp had declared force majeure on July 16. A force majeure event occurs when unforeseeable circumstances, such as natural disasters, prevent a party from fulfilling its contractual obligations and release it from sanctions.

A source at the company’s plants told S&P Global Platts that parts of the railroad in Hagen were “missing”, adding that it was even more difficult than before to get trucks for delivery. Hagen is a city in western Germany that has been hardest hit by the floods.

Floods in inland Henan cut the supply of wheat and coal

The disruption caused by the floods in China’s Henan Province, meanwhile, is made worse by the province’s being inland, Huxley said.

Read more about China from CNBC Pro

The interruption of the railway will again have “great effects”, he said.

“Of course that will affect the shipping, that will increase the shipping costs,” said Huxley.

The distribution of wheat and coal is affected, said Huxley, who pointed out that Henan is China’s “bread basket” and has produced 38 million tons of wheat this summer.

Categories
Politics

Biden Administration Strikes to Unkink Provide Chain Bottlenecks

WASHINGTON — The Biden administration on Tuesday planned to issue a swath of actions and recommendations meant to address supply chain disruptions caused by the coronavirus pandemic and decrease reliance on other countries for crucial goods by increasing domestic production capacity.

In a call on Monday evening detailing the plan to reporters, White House officials said the administration had created a task force that would “tackle near-term bottlenecks” in construction, transportation, semiconductor production and agriculture.

The officials also outlined steps that had been taken to address an executive order from President Biden that required a review of critical supply chains in four product areas where the United States relies on imports: semiconductors, high-capacity batteries, pharmaceuticals and their active ingredients, and critical minerals and strategic materials, like rare earths.

“This is about making sure the United States can meet every challenge we face in the new era,” Mr. Biden said in February, when he signed the order.

The review has been governmentwide, the officials said: Cabinet members were ordered to provide reports to the White House within 100 days. The move was intended to address concerns about supply chain resiliency and long-term competition with China.

The Department of Health and Human Services, for instance, will use $60 million from the $1.9 trillion coronavirus relief bill to develop technologies to increase domestic production of active ingredients in key pharmaceuticals. The Interior Department will work to identify sites where critical minerals could be produced in the United States. And several agencies will work on creating supply chains for new technologies that will reduce reliance on imports of key materials.

The Biden administration also signaled that it was prepared to use trade policy to bolster domestic supplies of key minerals and components. As part of that effort, the Office of the United States Trade Representative said it would establish a so-called strike force that could propose actions against overseas companies deemed to be engaged in unfair trade practices.

The Commerce Department will evaluate whether to investigate the global trade of neodymium magnets under Section 232 of the Trade Expansion Act of 1962. The Trump administration wielded that law to impose tariffs on foreign steel and aluminum, after concluding that domestic production of those materials was essential for national security.

As part of his plans to address climate change, Mr. Biden wants Americans to drive millions of new electric vehicles and get more of their energy from renewable sources like wind and solar power. But experts have long pointed out that the shift to cleaner energy will require vast supplies of critical minerals, many of which are currently produced and processed overseas.

Most of the world’s lithium, a key ingredient in the batteries that power electric vehicles, is mined in Australia, China, Chile and Argentina. China dominates global production of rare earth minerals such as neodymium, used to make magnets in wind turbines. It has also largely cornered the market in lithium-ion batteries, accounting for 77 percent of the world’s capacity for producing battery cells and 80 percent of its raw-material refining, according to BloombergNEF, an energy research group.

The United States lags far behind other countries in manufacturing many clean energy technologies, leaving it heavily reliant on imports.

The Biden administration has vowed to bring back more of that manufacturing and mining, but progress has been slow. In the United States, companies are racing to unlock lithium supplies in states like Nevada and North Dakota, though those efforts face opposition because of their environmental effects. The country also has only one mine that produces rare earth minerals, in Mountain Pass, Calif.

As part of its announcement on Tuesday, the Biden administration said it would work to identify new domestic sites where such critical minerals could be mined with environmental safeguards, asking Congress to increase funding for a mapping program at the U.S. Geological Survey.

The Energy Department announced that it would offer loans for companies that could sustainably refine, process and recycle rare earths and other materials used in electric vehicles. The agency on Tuesday will also release a plan to develop a domestic supply chain for lithium-ion batteries.

The Energy Department has $17.7 billion in authority to issue loans under the Advanced Technology Vehicles Manufacturing Loan Program, which Congress created in 2007 and used in 2010 to support the electric-vehicle manufacturer Tesla in its early days. In its announcement, the agency said it would seek to offer loans to manufacturers of advanced battery technology that established factories in the United States. It also announced a new policy in which future funding of new clean-energy technologies would require recipients to “substantially manufacture those products in the United States.”

Semiconductors — a key component in cars and electronic devices — were also another key research area for officials, though they did not describe immediate plans to increase production. A global semiconductor shortage has forced several American auto plants to close or scale back production and sent the administration scrambling to appeal to allies like Taiwan for emergency supplies. Instead, the 100-day review report said Congress should support a $50 billion investment in domestic semiconductor manufacturing and research.

The findings are partly a push for the president’s $1 trillion infrastructure plan, which could fund some of the research and job training to bring American workers up to speed on producing advanced technologies like semiconductors.

The effort comes as the Senate is poised to pass a huge industrial policy bill to counter China’s rising influence, a rare bipartisan development as lawmakers suddenly embrace an enormous investment in semiconductor manufacturing, artificial intelligence research, robotics, quantum computing and a range of other technologies.

Categories
Health

Provide chains could return to China amid Covid resurgence in India, Vietnam

The Covid-19 resurgence in some parts of Asia could lead to a change in fortunes for China, according to an economist.

Previously, the U.S.-China trade war caused companies to move their supply chains out of China, shifting their production and distribution networks for products and services. As a result, countries like Vietnam and India benefited as companies moved to set up shop in their countries.

But the situation appears to be changing, and supply chains could pivot back to China as cases spike in India and Vietnam, according to Zhang Zhiwei, chief economist at Pinpoint Asset Management.

Read more about China from CNBC Pro

“Before the pandemic, we saw factories moving out of China — Samsung, Foxconn these big name companies — setting up factories in Vietnam, India,” he told CNBC’s “Street Signs Asia” on Monday.

The spike in cases in those two countries has forced factories owned by Taiwanese contract manufacturer Foxconn, a major Apple supplier, to shut down facilities in India and Vietnam, he said.

“This could put the relocation of supply chains on hold for quite some time. The key issue here is that international travel is suspended, so multinational companies can’t send their staff to India and Vietnam to set up new factories,” Zhang added.

Cases in India surged to record-breaking highs in April and shows little signs of abating significantly —economists have predicted the South Asian economy will likely contract this quarter.

In Vietnam, the northern province of Bac Giang on Tuesday ordered four industrial parks — including three that house production facilities of Taiwan’s Foxconn — to temporarily shut down due to an outbreak of Covid-19.

The situation could benefit China, Zhang suggested. However, he pointed out that the extent of how much China could stand to gain will depend on how long the situation in India and Vietnam continues for.

Right now, export growth in China is between 20% to 40% a month, he said. If the factories in India and Vietnam return to production very soon, China’s exports would be expected to slow down in the second half of the year as companies move their manufacturing to those two countries.

“But if supply chain (in India and Vietnam) is disrupted for a long time, we could see this kind of 20%, 30% export growth (in China) to continue into next year,” Zhang said.

Categories
Health

Sure, Pot Is Authorized. However It’s Additionally in Brief Provide in NY and NJ

New York and New Jersey are all about growing legal weeds.

In Orange County, NY, plans to build a large cannabis cultivation and processing facility on the site of a defunct state prison.

About 25 miles south, across the border in New Jersey, an industrial complex that once belonged to pharmaceutical giant Merck is being converted into an even larger marijuana cultivation center.

In Winslow, New Jersey, about 30 miles outside of Philadelphia, a new indoor growing complex was just celebrating its first harvest.

The advent of legalized adult marijuana in New York and New Jersey is an entrepreneur’s dream. Some estimate that the potential market in the densely populated region will grow to over $ 6 billion in five years.

However, the rush to get plants in the ground at factory-style manufacturing facilities underscores another fundamental reality in the New York metropolitan area: there is already a shortage of legal marijuana.

In New Jersey’s decade-old medical marijuana market, the supply of dried cannabis flower, the strongest part of a female plant, has rarely met demand, according to industry lobbyists and state officials. At the beginning of the pandemic, when demand exploded, it became even scarcer, patients and business owners said.

The supply gap has narrowed as the nationwide supply of flowers and products made from a plant’s extracted oils more than doubled between last March and this spring. Still, patients and owners say pharmacies often sell popular varieties.

“There are very few stocks,” said Shaya Brodchandel, executive director of the Harmony Foundation in Secaucus, New Jersey and president of the New Jersey Cannabis Trade Association. “Almost no wholesale business. As we harvest, we bring it straight to retail. “

Harmony bought the former Merck property in Lafayette, New Jersey late last year and is awaiting approval to start construction, Brodchandel said.

Because marijuana is illegal under federal law and cannot be shipped across state lines, marijuana products sold in each state must also be grown and manufactured there.

The Bundesbankengesetz makes it nearly impossible for cannabis companies to get conventional funding, creating a high hurdle for small startups and a built-in advantage for multi-state and international companies with deep pockets.

Oregon, which issued thousands of grow licenses after legalizing marijuana six years ago, has an abundance of cannabis. But many of the other 16 states where non-medical marijuana is now legal have faced similar supply shortages as New York and New Jersey as production slowly increased to meet demand.

“Flowers are always short in a new market,” said Greg Rochlin, general manager of the Northeast Division of TerrAscend, a cannabis company operating in Canada and the United States that opened its 17th medical marijuana dispensary in New Jersey this month.

In New York, where the medical marijuana program is smaller and more restrictive than New Jersey’s, the product menu includes oils, tinctures, and finely ground flowers suitable for vaping. The sale of loose marijuana buds for smoking is banned, however, and only 150,000 of the state’s 13.5 million adults who are 21 years of age or older are registered as patients.

When demand was modest, there was little incentive to increase supply. Until now.

Adult marijuana sales could begin in New Jersey within a year and New York by early 2023, industry experts predict.

“I’d be a fool if I didn’t make the product,” said Ben Kovler, founder and general manager of Green Thumb Industries, a cannabis company with offices in both states.

“There isn’t much inventory,” he said at a moment when a “tidal wave” of demand was looming on the horizon. “It is unlikely that there will be enough supplies,” said Kovler.

His company, he said, is awaiting final New York State approval to begin construction on the site of the former Warwick, NY men’s Mid-Orange Correctional Facility, which closed in 2011.

The competitor Citiva is also building a new production center there. A cannabis test laboratory and a CBD extraction facility, urbanXtracts, are already in place.

“We call it a cannabis cluster,” said Michael Sweeton, Warwick’s city overseer.

“It’s the definition of irony,” he added of the reinvented role of a correctional facility that boomed during the war on drugs, imprisoning 750 men at the same time and providing 450 jobs.

New York officials said the state’s hemp farmers will play an important role in efforts to produce enough cannabis to satisfy what is set to quickly become one of the largest marijuana markets in the country.

With lower overheads and a lower carbon footprint, hemp farmers who grow cannabis for specific purposes could potentially undercut indoor plant prices for at least part of the year, authorities said. Hemp, which contains much less of the intoxicating chemical THC found in cannabis, is used to make CBD oil.

New York law also allows individuals to grow up to six marijuana plants for personal use. New Jersey law does not allow so-called home growth.

In the coming months, both states are expected to enact regulations to regulate the new industry. Everyone has classified legalization as a social justice imperative, spending a large portion of the expected tax revenue on color communities disproportionately harmed by inequalities in criminal justice.

Trying to balance the goal of building markets geared towards social and racial justice against the inherent dominance of multistate corporations with early stakes in the region will be vital, officials in New York and New Jersey said.

“They should have the ability to boost the market,” said Norman Birenbaum, New York’s director of cannabis programs, of the 10 medical marijuana companies that have already been licensed to operate in the state. But it shouldn’t come “at the expense of new entrants,” he said.

Jeff Brown, who heads New Jersey’s cannabis programs, said the market has room – and a critical need – for newcomers.

The current operators of the state, he said, “will not be able to supply the market for personal use.”

The granting of two dozen new drug licenses has been delayed by more than a year due to a legal challenge, and some of the 12 current operators, Brown said, have been slow to fully utilize their expandability.

This has put a limit on the amount of cannabis that can be sold to patients in a single visit. Lines to enter stores tightened by Covid-19 regulations are common.

“You can’t always find the strain that is best for your condition,” said Ken Wolski, a retired nurse who now leads the Medical Marijuana Coalition, a nonprofit advocacy group. “And that’s a very frustrating thing for patients.”

Supply chain challenges have taken on a new urgency in New Jersey, where the state’s medical marijuana dispensaries are expected to be the first places adults can legally purchase cannabis without a doctor’s approval.

First, however, pharmacies must demonstrate that they have adequate patient care and facilities that can adequately accommodate both types of customers.

The New Jersey market has grown since 2019 when Governor Philip D. Murphy, a Democrat, approved a major expansion of a medical marijuana program that failed under his predecessor, Chris Christie, a Republican.

The number of pharmacies has tripled. 500,000 plants are currently being grown across the state, up from 50,000 in 2018, Brown said.

In March, 20,000 pounds of cannabis products were available in New Jersey, up from 8,000 pounds in March, he said.

Still, the price of flowers in New Jersey fluctuates between $ 350 and $ 450 an ounce before discounts. In California, the average price of an ounce of premium marijuana was $ 260, according to priceofweed.com, a frequently quoted price list.

“Popular products are running out and prices are still higher than we’d like to see,” said Brown. “The key to all of this is more competition.”

Last month, Curaleaf, which operates a pharmacy and two grow facilities in New Jersey, lifted the half-ounce limit on flower sales after a strong yield at its new indoor grow facility in Winslow, said Patrik Jonsson, the company’s executive regional president for seven northeastern states.

Workers at a similarly sized cultivation facility in Boonton, New Jersey, operated by TerrAscend, placed hundreds of plants in coconut-coconut bundles in early 2021 to begin a four-month growing and drying process. Tiered platforms are now filled with rows of light green and purple colored plants.

TerrAscend’s new pharmacy in Maplewood, New Jersey, attracted a number of customers within hours of opening earlier this month.

Stuart Zakim, one of the first in line, spoke to a cashier – the “Budtender” – about alternatives to the product he had originally requested but was told it was out of stock.

“You no longer wait in the dark for your dealer,” said Mr. Zakim, a longtime medical marijuana patient. “You are going to a beautiful facility.”

“The supply problem,” he added, “is really the biggest problem.”

Categories
Business

Patent waivers and influence on world vaccine provide shortages

Losing intellectual property protection for Covid-19 vaccines will not help address global supply bottlenecks, the co-founder of a Massachusetts-based biopharmaceutical company told CNBC.

The demand for patent waivers is “political theater” and does not inherently allow others to make safe and effective vaccines that are already very difficult to make, said Jake Becraft, CEO and co-founder of Strand Therapeutics.

His company doesn’t make Covid-19 vaccines, but is developing a platform to develop programmable messenger RNA drugs that can trigger the body’s immune response to fight disease.

“We have to commit ourselves to what we already manufacture and scale this worldwide as much as possible,” Becraft said Monday in CNBC’s “Squawk Box Asia”.

Lack of vaccine

Due to the global shortage of Covid-19 vaccines, some countries have searched for supplies to launch their vaccination programs. Indeed, India – the world’s largest vaccine maker – is facing domestic shortages in the midst of a devastating second wave.

Health experts, rights groups and international medical charities have argued that there is an urgent need to abandon intellectual property rights in order to address the global vaccine shortage and avoid prolonging the health crisis. It is because many countries, especially in Asia, are affected by new waves of infections due to mutated Covid variants.

However, vaccine makers argue that such a move could disrupt the flow of raw materials and result in less investment by smaller biotech innovators in health research.

Last year India and South Africa submitted a joint proposal to The World Trade Organization waives intellectual property rights in Covid vaccines.

Known as Trips Waiver – or trade-related intellectual property rights – the plan has been blocked by some high-income countries, including the UK, Switzerland, Japan, Norway, Canada and the European Union. France, for example, argued that the way to step up global vaccination is for vaccine-producing nations to increase their exports.

While the United States initially blocked the proposal, the Biden government said earlier this month it supports the waiver of intellectual property rights for Covid-19.

Increase in the supply chain

Becraft said the vaccines have to be made in very controlled, high-tech facilities and that the technology required doesn’t exist around the world. This means that despite a patent waiver, some countries do not have the expertise to manufacture their own vaccines.

Instead, Becraft suggested incentivizing pharmaceutical companies like Moderna, Pfizer, and BioNTech to roll out the technology to manufacturing facilities around the world.

“If we want vaccines that are safe and effective, we need to encourage these companies to actually build manufacturing capacities around the world,” he said.

“We have to go to Moderna, we have to go to BioNTech and say, ‘What do you need to transfer your technology to these developing countries?'” Becraft said.

When vaccines aren’t available to everyone around the world, there’s always a risk of a variant of Covid that makes vaccines ineffective, he added. “All of our progress up to this point will be in vain.”

Nisha Biswal, president of the US-India Business Council, agreed that waiving a patent will not resolve the issue of increasing vaccine supply to the rest of the world.

With a patent waiver, it would take months or years for the technology, raw materials and production capacity to meet the required standard So that countries can manufacture their own vaccines, she told CNBC’s Squawk Box Asia on Monday.

Instead, the focus should be on helping countries that already make vaccines increase their production.

“Many of these (vaccine) manufacturers are already in discussions with India and Indian companies about how they can try to make some of these products in India,” said Biswal. “This is probably a faster and more efficient way than talking about no trips.”

Strand Therapeutics’ Becraft added that longer term, world governments need more funding and infrastructure support to provide pharmaceutical companies with manufacturing facilities around the world.

Last week BioNTech announced that it would set up a manufacturing facility in Singapore to manufacture its mRNA-based vaccines.

– CNBC’s Silvia Amaro contributed to the coverage.

Categories
Business

Goodyear CEO says firm has provide to blunt looming rubber scarcity

Rich Kramer, CEO of Goodyear Tire & Rubber, told CNBC on Tuesday that he did not expect an impending rubber shortage that could hurt the tire maker.

Concerns about low supply of rubber from rubber trees, most of which are grown in Southeast Asia, is the most recent problem facing automakers already facing semiconductor shortages.

When asked if the company has enough material to make tires for cars, Kramer said, “The short answer is, we do it.”

“Basically, you see … either speculation or even China [putting] Rubber in stores, “said Kramer in an interview with Jim Cramer about” Mad Money “.

“It’s something that’s always out there, there’s a lot of speculation,” he added. “I can never say anything about anything that could happen to Southeast Asian rubber trees, but that really wasn’t a problem for us and the team did a great job.”

Goodyear’s shares rose 3% on Tuesday before closing at $ 18.28.

Categories
Business

Covid vaccinations in U.S. are slowing as provide outstrips demand

After months of steady surge in vaccinations, the US is seeing its first real slowdown in the daily rate of fire, an indication that the nation is entering a new phase in its vaccination campaign.

More than half of American adults have now received at least one dose, a significant achievement, but vaccinating the second half presents other challenges. Previous vaccinations are likely made up largely of groups who wanted and had the greatest access to the vaccine, and as progress continues, it is no longer about meeting the demand for vaccination.

“We have had vaccinations against those who are most at risk and who are most likely to want to be vaccinated as soon as possible,” White House Tsar Covid Jeff Zients told reporters last week. “We will continue these efforts, but we know that we will reach other populations.” Take your time and focus. “

The country averaged 2.6 million reported vaccinations per day for the past week, data from the Centers for Disease Control and Prevention shows, from a peak of 3.4 million reported shots per day on April 13. That number is falling, even if the eligibility is now open to all adults in every state.

The downturn There is a lot of positive vaccination news to follow, said Dr. Jennifer Kates, senior vice president of the Kaiser Family Foundation’s nonprofit health policy group. The federal government has ensured a large supply of vaccines, states have ironed out kinks in their registration systems, and eligibility has opened up to all adults.

Kates says that meeting existing vaccine needs is no longer the biggest challenge.

“We feel like we’ve got to a point where the people who are left are very hard to reach and need help and more education, or those who are resilient and don’t want to,” she said adding, “the Pent-up demand will be met.”

The question is, what will the answer to the slowdown be? “How do the federal, state and private sectors communicate the importance of vaccination to the public?” Asked Kates.

States are seeing a slowdown in demand

In parallel with the nationwide slowdown, the rate of vaccination is falling in many countries. Eleven states have reported a decrease in shots fired for three consecutive weeks or more, according to a CNBC analysis of the CDC data through Sunday.

In West Virginia, which is off to a hot start with its vaccination campaign, the state has passed the tipping point where vaccine supply exceeded demand. The weekly doses have been decreasing for four consecutive weeks.

“If you remember, we were putting a lot of doses in many arms very quickly,” said Maj. Gen. James Hoyer, director of the Joint Interagency Task Force on Vaccines in West Virginia, noting that his state was among the first to get vaccinations have completed among nursing home populations. “There were a lot of people who wanted her and tried very hard to get out and get a vaccine.”

Now, Hoyer said, the state has asked the federal government to dispense doses in smaller vials to reduce the risk of wasting vaccines, which he could not have imagined a few months ago with such a small supply.

“We got the doses and we’re really good at administering them,” said Hoyer. “We are at this stage of educating people who cannot get the vaccine.”

New Mexico led the country for a while, with a greater proportion of the population fully vaccinated than any other state.

But now the state is facing a plateau and finding it harder to fill mass vaccination events, said Matt Bieber, communications director for the state’s health department.

“We’ve been in a period of tons of demand and not enough supply, but now at the point where people who know about the vaccine got it,” he said.

Logistic hurdles

The proportion of Americans who have not yet received a Covid shot is not made up entirely of those who do not want one.

While some oppose it – in a recent Kaiser Foundation survey, 13% of respondents said they would “definitely not” get a vaccine and another 7% said they would only get one if needed – there is, too many groups who have not yet had the resources or the ability to get vaccinated.

“Some people can’t take time off work to get easily vaccinated, or they may not have transportation,” Kates said, explaining that sometimes lack of access is purely logistical. “You literally have no access in the most basic of ways.”

Hoyer said many West Virgins cannot afford to sacrifice hours of wages to leave work for an appointment. His most successful form of public relations has been offering vaccinations to employees and their families in local workplaces, where people can take 30 minutes off shift to get a chance. A recent event at a Toyota manufacturing facility in Putnam County, West Virginia, resulted in more than 1,000 vaccinations.

Bieber in New Mexico has received similar feedback. He heard from community members that a group of grocers would like to be vaccinated, but they are working on shifts that last beyond the hours their local clinic is open. Mobile vaccination units that give people shots can help with such logistical challenges, he said.

The lack of internet access is another obstacle to getting vaccination appointments, most of which were previously booked online, said Dr. Rupali Limaye, a faculty member at the Johns Hopkins Bloomberg School of Public Health who is involved in vaccine decision making and in state health departments during the vaccine rollout. She said this was particularly evident in states with higher proportions of black residents who are traditionally less likely to have internet access.

Rural communities in West Virginia and New Mexico may also have limited internet access, Hoyer and Bieber said.

public relation

Other barriers to access to vaccines are misinformation or lack of education about the safety of vaccines.

For groups facing more than logistical problems, states turn to community leaders and organizations for help with outreach and education.

New Mexico is working with health care providers to leverage patient relationships to discuss vaccinations. Virtual town halls have also been set up to answer questions from community groups such as the Black and Hispanic residents of the state and the farm laborer population.

City halls usually lead to a surge in vaccine registration, Bieber says, but progress is slower than in the earlier days of the vaccination campaign.

“At a time when we can easily run a mass vaccination event, the point is to convince people by the dozen, dozen, or even one at a time,” he said.

For example, Arkansas works with health professionals, religious and community leaders, and the Chamber of Commerce to disseminate information about vaccines, said Dr. Jennifer Dillaha, epidemiologist and medical director for vaccinations at the state health department. Some people want a familiar, trustworthy environment in which to raise concerns and answer questions, she said.

In East New York, Brooklyn, vaccines were initially not widespread for residents, although they were disproportionately affected by Covid, according to Colette Pean, executive director of the East New York Restoration community organization.

Local residents in the neighborhood have high rates of pre-existing health conditions such as diabetes and asthma, and many are key employees in grocery stores, nursing homes, and the transit department. A New York Times database shows about 20% of residents with at least one dose of vaccine in East New York, compared with 30% in the entire city and more than 40% in many parts of Manhattan.

People want to get the vaccine, Pean said, but need to know where to get it, which is better communicated through a personal approach than a digital one. Her group works in churches, pantries, and subway stations to share information about vaccines and public health issues, Covid and others, that exist in the community.

Johnson & Johnson are taking a break

Earlier this month, the Food and Drug Administration and CDC urged states to temporarily stop using the Johnson & Johnson vaccine “out of caution” after reports that six women had developed rare blood clots. U.S. health officials lifted the 10-day break last week, saying the benefits of the shot outweigh the risk.

So, did the J&J hiatus play a role in the drop in vaccinations? Kates said it wasn’t enough to explain the whole slowdown story.

Only about 8.2 million of the 237 million recordings filed in the US to date are from J&J, although they were used for an average of 425,000 reported recordings per day in mid-April.

The single shot option, which is also easier to transport and store, has proven useful in certain situations and communities, such as: B. in mobile vaccination units and for homeless people who have several difficulties accessing a vaccination center.

“We know that there are some populations who wanted the single dose or were harder to reach and that a single point of contact is ideal, so it is possible that some people were not vaccinated for this reason,” she said. “But on the whole, being a big change is not enough.”

If you only take into account the recordings from Pfizer-BioNTech and Moderna, the downward trend remains. The combination of these two vaccines peaked on April 16, averaging 3 million reported daily shots, and has since declined 13%.

The grimmer question, however, is whether the J&J stop affects confidence in the safety of vaccines in the broader sense and reduces the likelihood of Americans receiving a dose of any of the three vaccine options.

The J&J shot may have been more appealing to those who were initially reluctant to get a vaccine. Polls by the Kaiser Family Foundation in March found that among those who said they’d like to see how the vaccines work before being self-vaccinated, a greater proportion would receive the J&J single-dose vaccine compared to either Dosage options.

However, Kates doesn’t think the J&J hiatus was a major factor behind the vaccine’s hesitation. “As far as I know, the confidence hasn’t been shaken at all,” she said.

Categories
World News

Africa’s Vaccine Drive Is Threatened by India’s Provide Halt

NAIROBI, Kenya – The rapidly escalating coronavirus crisis in India is not only forcing hospitals to ration oxygen, it is sending families to find open beds for infected relatives. It is also wreaking havoc on vaccination efforts around the world.

Nowhere is this more evident than in Africa.

Most nations relied on vaccines made in the Serum Institute factory in India. However, the Indian government’s decision to restrict can exports as it deals with its own outbreak means that Africa’s already slow vaccination campaign could soon come to a standstill.

Before India stopped exporting, more than 70 nations received vaccines it had made with a total of more than 60 million doses. Many went to low and middle income countries as part of the Covax program, the global initiative to ensure equitable access to vaccines.

To date, Covax has dispensed 43.4 million doses in 119 countries, but that’s only about 2 percent of the two billion doses expected to be dispensed this year, according to Andrea Taylor, associate director at Duke Global Health Innovation Center.

“Export controls from India are the main limitation on Covax’s current offering,” she wrote in an email.

Even before India stopped shipping, Africa saw the slowest vaccine introduction of any continent. As of April 21, African nations, with a total population of 1.3 billion, had received more than 36 million doses of vaccine, but administered only about 15 million, according to the African Centers for Disease Control and Prevention.

What You Need To Know About The Johnson & Johnson Vaccine Break In The United States

    • On April 23, an advisory panel to the Centers for Disease Control and Prevention voted to lift a hiatus on Johnson & Johnson Covid vaccine and put a label on an extremely rare but potentially dangerous bleeding disorder.
    • Federal health officials are expected to officially recommend states lift the hiatus.
    • The vaccine was recently discontinued after reports of a rare bleeding disorder surfaced in six women who received the vaccine.
    • The overall risk of developing the disorder is extremely small. Women between the ages of 30 and 39 appear to be most at risk, with 11.8 cases per million doses. There were seven cases per million doses in women between 18 and 49 years of age.
    • Almost eight million doses of the vaccine have now been given. There was less than one case per million doses in men and women aged 50 and over.
    • Johnson & Johnson had also decided to postpone the launch of its vaccine in Europe for similar reasons, but later decided to continue its campaign after the European Union Medicines Agency announced the addition of a warning. South Africa, devastated by a contagious variant of the virus, also stopped using the vaccine, but later continued to use it.

Only six million doses were administered in all of sub-Saharan Africa – fewer than many individual US states. The prospect of a reduction in supply complicates the already enormous logistical challenge for many African nations.

Many African governments prioritized giving initial doses to more of their populations in the expectation that more doses would arrive soon. Now they are struggling with what to do when there aren’t enough vaccines to get the full two-dose regimen that provides maximum prevention.

Countries like Rwanda and Ghana, which were among the first to receive doses of Covax, are about to run out of initial supplies. In Botswana, vaccinations were temporarily suspended in some areas this month after the allotted doses ended. And Kenya, which is nearing its initial 1 million dose, said this week it would try to acquire vaccines from Johnson & Johnson and Pfizer to continue its vaccination campaign. On Saturday, due to delays, the country extended the time between first and second dose administration from eight to 12 weeks.

Overall, the 10 African countries that have had the most vaccinations have gone through more than two-thirds of their deliveries, said Dr. Matshidiso Moeti, World Health Organization Regional Director for Africa.

The African Union Vaccination Group has secured funding to purchase up to 400 million Johnson & Johnson vaccines for member states – but those doses will not arrive until the fall.

“More than a billion Africans are on the verge of this historic march to end this pandemic,” said Dr. Moeti.

A spokesman for Gavi, who heads the Covax program, said in an email that it was in close contact with the Indian government about resuming vaccine shipments, but that “we cannot confirm the timing of the next shipments at this stage . “

Even if the United States is betting on tens of millions of doses of the AstraZeneca vaccine – the most affordable vaccine that is widely available – African nations are turning to Russia and China for doses in those countries, despite concerns about a lack of clinical data on its effectiveness pass and security.

Amid the delays, some African countries are facing new and potentially more deadly waves of the pandemic. The African Centers for Disease Control and Prevention reported 2,155 deaths from the virus in the past week, up from 1,866 the week before.

In Nairobi, the capital of Kenya and home to one of the better health systems on the continent, officials have warned of a lack of intensive care beds and oxygen supplies. Last month, the Kenyan government ordered a new lockdown, which has fueled anger over the economic impact of the restrictions.

Categories
Health

U.S. Covid vaccination impediment shifts in direction of lack of demand from scarce provide, warns physician

Dr. Carlos Del Rio said US Covid cases could decline dramatically into May as long as the US continues to aggressively vaccinate and convince reluctant communities to get vaccinated.

“I worry … that we are quickly moving our country from a supply problem, a vaccine shortage problem, to a demand problem,” said Del Rio. “I’ll tell you that the most reluctant communities are mostly white evangelicals, and we really need to go to these communities to vaccinate them.”

There are roughly 41 million white evangelical adults in the U.S. and roughly 45% said they wouldn’t be vaccinated against Covid-19 in late February, which makes them the least likely population group to do so, according to the Pew Research Center.

Half of all American adults have received at least one dose of a coronavirus vaccine. Of those 65 years old and older, 81% have received one dose or more, and about two-thirds are fully vaccinated, according to the Centers for Disease Control and Prevention.

Del Rio, a professor of medicine who specializes in infectious diseases at Emory University School of Medicine, told CNBC’s “The News with Shepard Smith” that the US may be able to follow Israel’s example and requirements Increasing masking outdoors when transmission in the community drops.

“If we can reduce community transmission to below ten cases per 100,000 population, I don’t think it will be necessary to wear masks outdoors,” said Del Rio.

Host Shepard Smith also asked Del Rio about Texas and those citing the state as an example of successful mask mandate lifting. According to Johns Hopkins University, the average daily Covid cases in Texas have dropped 41% since Governor Greg Abbott lifted the mask mandate 40 days ago. Del Rio noted that there are still many unknowns about Covid and that states should still proceed with caution in lifting Covid restrictions.

“I think sometimes we wonder if a place like Texas is good or happy, and I think it’s luckier than good, frankly,” said Del Rio.

CDC director Dr. Rochelle Walensky has warned that Americans should still be on guard over Covid.

Categories
Politics

White Home to host Google, Intel CEOs to debate chip provide chain

President Joe Biden holds a chip in his hand before speaking in the State Dining Room of the White House in Washington, USA, on February 24, 2021, ahead of the signing of an ordinance to remedy a global semiconductor shortage.

Jonathan Ernst | Reuters

Executives from companies like Google parent Alphabet, AT&T, Intel and General Motors will attend a virtual summit at the White House on Monday to address the global semiconductor shortage.

The summit comes when the Biden administration embarks on a review of key U.S. supply chains, including those for semiconductors, high-capacity batteries, medical supplies and rare earth metals. The shortage of computer chips is affecting a number of industries, from electric vehicle manufacturers to medical supplies.

Automakers like GM and Ford recently had to cut production estimates or extend downtime to address the shortage. The supply chain was initially at risk at the start of the Covid pandemic, as a large part of the world’s chips are manufactured in Asia, where the crisis first appeared.

US officials and lawmakers have highlighted the potential safety implications of the country’s reliance on other countries for semiconductors. Senate Majority Leader Chuck Schumer, DN.Y., said in February that “semiconductor manufacturing is a dangerous flaw in our economy and national security.”

For economic and national security reasons, the supply chain assessment set out in Biden’s February Executive Order seeks to assess “the resilience and capacity of America’s manufacturing and industrial defense base supply chains in support of national security [and] Emergency preparedness. “

The White House has also said it is trying to fill gaps in domestic production and supply chains that are “dominated or passed through nations that are becoming or becoming unfriendly or unstable”.

While the White House review does not specifically mention China, the directive is likely largely an attempt by the government to determine how dependent the US economy and military are on a critical group of Chinese exports.

According to the White House, the virtual summit will be hosted by National Security Advisor Jake Sullivan and NEC Director Brian Deese, and Secretary of Commerce Gina Raimondo. Attendees will discuss Biden’s American employment plan and strengthening the U.S. semiconductor supply chain, according to the White House.

Here is the full list of companies whose executives are expected to attend the summit:

Subscribe to CNBC on YouTube.

WATCH: Chip scarcity is slowing production of game consoles, cars, and more